Monitoring of immune responses following COVID-19 infection or vaccination in Bobo-Dioulasso, Burkina Faso

Monitoring of immune responses in post-SARS-CoV-2-infection and post-vaccination against COVID-19 in Bobo-Dioulasso, Burkina Faso

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN41192701

Enrollment

300

Registered

2024-03-23

Start date

2022-02-21

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 (SARS-CoV-2 infection) Infections and Infestations

Interventions

Monitoring of serology and T-cell responses (ancillary study in a small group of volunteers) post-infection of former COVID-19 patients confirmed previously monitored by the Bobo-Dioulasso COVID-19 me

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Any former COVID-19 patient over the age of 18 years, with a documented PCR test at most 2 years before recruitment, whether they have been followed on the COVID-19 care site or at home Or 2. Any adult over the age of 18 years ready to receive any COVID-19 vaccination wishing to take part in the study and residing in Bobo-Dioulasso in Burkina Faso

Exclusion criteria

Exclusion criteria: 1. Any former patients whose PCR test confirming infection is not documented will be excluded from the post-infection cohort. 2. Anyone who has already received a dose of vaccine at the time of inclusion in the study will not be included in the post-vaccination cohort

Design outcomes

Primary

Measure	Time frame
Serum anti-SARS-CoV-2 IgG concentration measured with Luminex at day 0, day 28, month 3, month 6 and month 12 post-vaccination and month 6, month 12 and month 24 post-infection	—

Secondary

Measure	Time frame
1. Serum-neutralizing antibody concentration measured using a luciferase sero-neutralization test at day 0, day 28, month 3, month 6 and month 12 post-vaccination and month 6, month 12 and month 24 post-infection 2. Salivary anti-SARS-CoV-2 IgG concentration measured using Luminex technology at day 0, day 28, month 3, month 6 and month 12 post-vaccination and month 6, month 12 and month 24 post-infection 3. Exposure to helminths assessed by ELISA tests at baseline An ancillary study with 50 participants per group will assess the cellular immune response (CD4+ and CD8+ T cells) by flow cytometry and cellular phenotyping at day 0, day 28, month 3, month 6 and month 12 post-vaccination and month 6, month 12 and month 24 post-infection	—

Measure

Time frame

1. Serum-neutralizing antibody concentration measured using a luciferase sero-neutralization test at day 0, day 28, month 3, month 6 and month 12 post-vaccination and month 6, month 12 and month 24 post-infection 2. Salivary anti-SARS-CoV-2 IgG concentration measured using Luminex technology at day 0, day 28, month 3, month 6 and month 12 post-vaccination and month 6, month 12 and month 24 post-infection 3. Exposure to helminths assessed by ELISA tests at baseline An ancillary study with 50 participants per group will assess the cellular immune response (CD4+ and CD8+ T cells) by flow cytometry and cellular phenotyping at day 0, day 28, month 3, month 6 and month 12 post-vaccination and month 6, month 12 and month 24 post-infection

—

Countries

Burkina Faso

Contacts

Public ContactHoureratou Barry

houreratou.barry@centre-muraz.bf+(226) 66 55 81 56

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026